ClinicalTrials.Veeva

Menu

Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk

University of Wisconsin (UW) logo

University of Wisconsin (UW)

Status

Completed

Conditions

Breast Cancer Risk

Study type

Observational

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT00839696
CC07104
SMPH/POP HEALTH SCI (Other Identifier)
A538500 (Other Identifier)
2008-1013 (Other Identifier)

Details and patient eligibility

About

Mammographic density is sensitive to estorgen exposure and constitutes a strong intermediate maker of breast cancer risk. We hypothesize that women with higher serum xenoestrogen levels will have greater mammographic density.

Enrollment

270 patients

Sex

Female

Ages

55 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 55-70 years of age, Post menopausal

Exclusion criteria

  • If they have ever used hormone replacment therapy or have ever used Tamoxifen or Raloxifene, Diag. with breast cancer have had breast implants or have had a mastectomy/

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems